Literature DB >> 18813903

[Value of lymphadenectomy for limited nodal recurrence of prostate cancer after local therapy with curative intent].

I Wolff1, M-O Grimm, M Wirth.   

Abstract

After local therapy for prostate cancer, presumably isolated nodal recurrence is being detected in increasing numbers of patients by modern imaging techniques, especially by positron emission tomography (PET). The question arises whether lymphadenectomy may delay tumor progression.Conclusions concerning the value of PET/computed tomography, perioperative complications, and oncological outcome were derived from available studies and our own experiences. Six studies reported on 83 patients who underwent lymphadenectomy for suspected nodal recurrence. In cases with histological confirmation, no patient was cured.Hence, nodal recurrence in prostate cancer most likely represents a systemic affection instead of locally limited disease. If a drop in the prostate-specific antigen level occurs after lymphadenectomy, it can be assumed that the progression-free period is expected to be less than 12 months.The available data on oncological outcomes of this procedure are insufficient. Therefore, lymphadenectomy for nodal recurrence of prostate cancer remains an unproven approach.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18813903     DOI: 10.1007/s00120-008-1723-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  22 in total

1.  11C-choline positron emission tomography in prostate cancer: primary staging and recurrent site staging.

Authors:  Soichiro Yoshida; Kazuaki Nakagomi; Shuichi Goto; Masami Futatsubashi; Tatsuo Torizuka
Journal:  Urol Int       Date:  2005       Impact factor: 2.089

2.  11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse.

Authors:  Nobuyuki Oyama; Tom R Miller; Farrokh Dehdashti; Barry A Siegel; Keith C Fischer; Jeff M Michalski; Adam S Kibel; Gerald L Andriole; Joel Picus; Michael J Welch
Journal:  J Nucl Med       Date:  2003-04       Impact factor: 10.057

3.  Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA < 5 ng/ml?

Authors:  Martin Heinisch; Albert Dirisamer; Wolfgang Loidl; Franz Stoiber; Bernhard Gruy; Silke Haim; Werner Langsteger
Journal:  Mol Imaging Biol       Date:  2006 Jan-Feb       Impact factor: 3.488

4.  The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.

Authors:  David S DiMarco; Horst Zincke; Thomas J Sebo; Jeffrey Slezak; Erik J Bergstralh; Michael L Blute
Journal:  J Urol       Date:  2005-04       Impact factor: 7.450

5.  Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer.

Authors:  Ludwig Rinnab; Felix M Mottaghy; Norbert M Blumstein; Sven N Reske; Richard E Hautmann; Kathrin Hohl; Peter Möller; Thomas Wiegel; Rainer Kuefer; Juergen E Gschwend
Journal:  BJU Int       Date:  2007-10       Impact factor: 5.588

6.  Omission of lymphadenectomy in low risk prostate cancer.

Authors:  Angelo Naselli; Rossana Andreatta; Carlo Introini; Vincenzo Fontana; Paolo Puppo
Journal:  Anticancer Res       Date:  2007 Nov-Dec       Impact factor: 2.480

7.  Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy.

Authors:  Vincenzo Scattoni; Maria Picchio; Nazareno Suardi; Cristina Messa; Massimo Freschi; Marco Roscigno; Luigi Da Pozzo; Aldo Bocciardi; Patrizio Rigatti; Ferruccio Fazio
Journal:  Eur Urol       Date:  2007-03-20       Impact factor: 20.096

8.  Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer.

Authors:  David Schilling; Heinz P Schlemmer; Philipp H Wagner; Patrick Böttcher; Axel S Merseburger; Philip Aschoff; Roland Bares; Christa Pfannenberg; Ute Ganswindt; Stefan Corvin; Arnulf Stenzl
Journal:  BJU Int       Date:  2008-04-11       Impact factor: 5.588

9.  11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer.

Authors:  I J de Jong; J Pruim; P H Elsinga; W Vaalburg; H J A Mensink
Journal:  Eur Urol       Date:  2003-07       Impact factor: 20.096

Review 10.  Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy.

Authors:  Axel Heidenreich; Carsten H Ohlmann; Sergej Polyakov
Journal:  Eur Urol       Date:  2007-04-11       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.